These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 12901232

  • 61. Membrane proteins: the key players of a cancer cell.
    Kampen KR.
    J Membr Biol; 2011 Jul; 242(2):69-74. PubMed ID: 21732009
    [Abstract] [Full Text] [Related]

  • 62. Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization Via Inhibition of VEGF Production.
    Miyagawa T, Chen ZY, Chang CY, Chen KH, Wang YK, Liu GS, Tseng CL.
    Pharmaceutics; 2020 Apr 28; 12(5):. PubMed ID: 32354067
    [Abstract] [Full Text] [Related]

  • 63. Translocating a High-Affinity Designer TIMP-1 to the Cell Membrane for Total Renal Carcinoma Inhibition: Putting the Prion Protein to Good Use.
    Jiang B, Xu Y, Zhang Y, Lee MH.
    Mol Cell Biol; 2019 Sep 15; 39(18):. PubMed ID: 31208977
    [Abstract] [Full Text] [Related]

  • 64. Preclinical SPECT Imaging of Choroidal Neovascularization in Mice Using Integrin-Binding [99mTc]IDA-D-[c(RGDfK)]2.
    Ahn SJ, Lee HY, Hong HK, Jung JH, Park JH, Park KH, Kim SE, Woo SJ, Lee BC.
    Mol Imaging Biol; 2019 Aug 15; 21(4):644-653. PubMed ID: 30460625
    [Abstract] [Full Text] [Related]

  • 65. 18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging.
    Hu K, Tang X, Tang G, Yao S, Yao B, Wang H, Nie D, Liang X, Tang C, He S.
    PLoS One; 2015 Aug 15; 10(9):e0138675. PubMed ID: 26397833
    [Abstract] [Full Text] [Related]

  • 66. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q.
    Int J Nanomedicine; 2013 Aug 15; 8():2473-85. PubMed ID: 23885174
    [Abstract] [Full Text] [Related]

  • 67. Gene expression profiling of the anti-glioma effect of Cilengitide.
    Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J, Shimazu Y, Chiocca EA, Kaur B, Date I.
    Springerplus; 2013 Dec 15; 2(1):160. PubMed ID: 23667810
    [Abstract] [Full Text] [Related]

  • 68. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
    Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB.
    Anticancer Drugs; 2013 Mar 15; 24(3):237-50. PubMed ID: 23275294
    [Abstract] [Full Text] [Related]

  • 69. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
    Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I.
    Neuropathology; 2013 Apr 15; 33(2):162-74. PubMed ID: 22989076
    [Abstract] [Full Text] [Related]

  • 70. Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas.
    Fabricius EM, Wildner GP, Kruse-Boitschenko U, Hoffmeister B, Goodman SL, Raguse JD.
    Exp Ther Med; 2011 Jan 15; 2(1):9-19. PubMed ID: 22977464
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
    O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P, CNTO 95 Investigators.
    Br J Cancer; 2011 Jul 26; 105(3):346-52. PubMed ID: 21750555
    [Abstract] [Full Text] [Related]

  • 74. Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization.
    Salehi-Had H, Roh MI, Giani A, Hisatomi T, Nakao S, Kim IK, Gragoudas ES, Vavvas D, Guccione S, Miller JW.
    PLoS One; 2011 Apr 29; 6(4):e18864. PubMed ID: 21559527
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.
    Ye Y, Xu B, Nikiforovich GV, Bloch S, Achilefu S.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2116-20. PubMed ID: 21349709
    [Abstract] [Full Text] [Related]

  • 77. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.
    Reynolds AR.
    Dose Response; 2010 Apr 23; 8(3):253-84. PubMed ID: 20877487
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.
    Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ.
    Nucl Med Biol; 2009 Apr 23; 36(3):277-85. PubMed ID: 19324273
    [Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.